Back to School: How biopharma can reboot drug development. Access exclusive analysis here

NIH files its own BRCA1 patent

WASHINGTON - Rep. Ron Wyden has injected himself into the negotiations between the NIH and Myriad Genetics Inc. over the ownership of the BRCA1 breast cancer gene, declaring his continuing interest in the "leverage" that the NIH or other federal agencies can use to lower prices on new drugs or devices.

The issue centers on a patent on the BRCA1 gene filed by the University of Utah and licensed exclusively to Myriad (see BioCentury, Oct. 24). The patent does not

Read the full 793 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE